FlexPharma (FLKS:NASDAQ)

FlexPharma (FLKS:NASDAQ)

FlexPharma (FLKS:NASDAQ) has a $215M market cap. Flex Pharma speaks to a one of a kind biotech play in that it is building up a shopper item—a beverage—for competitors experiencing muscle spasms.

The organization’s objective business sector, leg spasms and spasticity, has generous potential, and Flex has various items in the pipeline too. As far as danger, an unassuming buyer rollout of the beverage item is normal in 2016; the organization has constrained restrictive protected innovation and is an early phase of advancement.

LKS raised net continues of $79.9mil at $16 per share, and the stock topped in April 2015 close $22 per offer. By July 2015, the biotech business topped, it’s still one of the main segments failing to meet expectations in the late positively trending market. FLKS has been in a downtrend as it has quickly blazed a money heap from the season of the IPO of $115mil to $84mil in the latest quarter.

Basically, FLKS is an organization that ought to have been left hatching for a couple of more years before coming to advertise. At its dispatch, it was a biotech “organization” with zero income and zero clinical trials endeavoring to make a plan of action out of a thought invoked in a Massachusetts kitchen by two spasmed up kayakers with a cause.

FLKS has a two dimensional methodology. In the first place, it is conveying to advertise a supplement in view of concentrates found in red bean stew peppers, cinnamon and ginger. The supplement, which is in a shot structure like that of 5-hour ENERGY popularity, just went live on May 31st and is called “Superstar.”

The slogan on its site understands, “We Just Un-created Muscle Cramps.” Catchy. With the supplement, it claims it is making a “progressive new classification in games nourishment” (that it simply made up) called Neuro Muscular Performance. We are exceptionally wary of its go-to-business sector system for this supplement.

While it is getting the word out on the supplement, the organization is starting clinical trials for its lead drug applicant, FLX-787. FLX-787 depends on the same fixing separates found in the supplement. It is looking for endorsement for treatment of nighttime leg spasms (NLCs) and treatment of spasticity in different sclerosis (MS) and amyotrophic parallel sclerosis (ALS) patients.

Share This: